HER2-Directed Agents in NSCLC
Dr Wade Thomas Iams explains how trastuzumab deruxtecan became the standard-of-care for HER2-mutated non-small cell lung cancer.
EP: 1.Overview of Antibody Drug Conjugates in Lung Cancer
EP: 2.ADCs in Development for the Treatment of Lung Cancer
EP: 3.Targeting CEACAM5 in Patients with Non-Small Cell Lung Cancer
Now Viewing
EP: 4.HER2-Directed Agents in NSCLC
EP: 5.Targeting HER3 in EGFR-Mutant NSCLC
EP: 6.Exploring TROP2 Expression in Patients with NSCLC
Related Videos
Related Content
